Ying Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Kong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Quhuan Li
School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China
4 shared publications - Ruiting Huang
School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China
3 shared publications - Zhiqing Luo
School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China
3 shared publications - Dongshan Sun
Institute of Biomechanics, School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China
1 shared publication - Dongshan Sun
School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, China
1 shared publication - Fengxia Zhang
Department of Nephrology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
1 shared publication
Latest Publications
- Open Access
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44733
m6A RNA methylation regulator heterogeneous nuclear ribonucleoprotein C: A prognostic biomarker for invasive ductal carcinoma validated through Mendelian randomization and transcriptome analyses
Although aberrant N6-methyladenosine (m 6 A) RNA methylation has been linked to oncogenesis and tumor progression, the association between the deregulation of m 6 A regulators and invasive ductal carcinoma (IDC), the predominant subtype of breast cancer, remains unclear. In this study, we sought to determine the function of m 6 A RNA methylation regulators in IDC, with a particular focus on assessing their potential as prognostic biomarkers. To identify dysregulated m 6 A RNA methylation regulators, we systematically analyzed 656 samples from patients with IDC and 81 normal samples from The Cancer Genome Atlas (TCGA) database, and Cox univariate, LASSO-Cox regression, and stepwise regression analyses were conducted to construct a risk-prediction model for determining patient prognosis. Subsequently, we evaluated the prognostic value of the risk signature in IDC and assessed potential biological associations based on clinical survival analyses, examination of publicly available immunohistochemical staining data from the Human Protein Atlas, and two-sample Mendelian randomization. Among the IDC samples, we identified 12 m 6 A RNA methylation regulators characterized by significant dysregulation. Subsequently, a 4-gene signature comprising heterogeneous nuclear ribonucleoprotein C ( HNRNPC ), YTH domain-containing family proteins 2 and 3 ( YTHDF2/3 ), and RNA-binding motif protein 15B ( RBM15B ) was constructed using machine learning algorithms. This signature was established to be an independent prognostic factor, particularly in patients with early stage IDC, and within the signature, HNRNPC was identified as a pivotal gene, the expression levels of which were demonstrated to be causally associated with the risk of IDC. On the basis of our findings in this study, we established a prognostic signature for IDC and identified a causal association between the expression of the signature gene HNRNPC and IDC risk. These findings indicate that m 6 A RNA methylation regulators could serve as molecular biomarkers for IDC and contribute to guiding therapeutic strategies.
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44733
Open Accessm6A RNA methylation regulator heterogeneous nuclear ribonucleoprotein C: A prognostic biomarker for invasive ductal carcinoma validated through Mendelian randomization and transcriptome analyses
Although aberrant N6-methyladenosine (m 6 A) RNA methylation has been linked to oncogenesis and tumor progression, the association between the deregulation of m 6 A regulators and invasive ductal carcinoma (IDC), the predominant subtype of breast cancer, remains unclear. In this study, we sought to determine the function of m 6 A RNA methylation regulators in IDC, with a particular focus on assessing their potential as prognostic biomarkers. To identify dysregulated m 6 A RNA methylation regulators, we systematically analyzed 656 samples from patients with IDC and 81 normal samples from The Cancer Genome Atlas (TCGA) database, and Cox univariate, LASSO-Cox regression, and stepwise regression analyses were conducted to construct a risk-prediction model for determining patient prognosis. Subsequently, we evaluated the prognostic value of the risk signature in IDC and assessed potential biological associations based on clinical survival analyses, examination of publicly available immunohistochemical staining data from the Human Protein Atlas, and two-sample Mendelian randomization. Among the IDC samples, we identified 12 m 6 A RNA methylation regulators characterized by significant dysregulation. Subsequently, a 4-gene signature comprising heterogeneous nuclear ribonucleoprotein C ( HNRNPC ), YTH domain-containing family proteins 2 and 3 ( YTHDF2/3 ), and RNA-binding motif protein 15B ( RBM15B ) was constructed using machine learning algorithms. This signature was established to be an independent prognostic factor, particularly in patients with early stage IDC, and within the signature, HNRNPC was identified as a pivotal gene, the expression levels of which were demonstrated to be causally associated with the risk of IDC. On the basis of our findings in this study, we established a prognostic signature for IDC and identified a causal association between the expression of the signature gene HNRNPC and IDC risk. These findings indicate that m 6 A RNA methylation regulators could serve as molecular biomarkers for IDC and contribute to guiding therapeutic strategies.
- Open Access
LncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas
Gliomas are the most prevalent primary malignant tumors affecting the brain, with high recurrence and mortality rates. Accurate diagnoses and effective treatment challenges persist, emphasizing the need for identifying new biomarkers to guide clinical decisions. Long noncoding RNAs (lncRNAs) hold potential as diagnostic and therapeutic biomarkers in cancer. However, only a limited subset of lncRNAs in gliomas have been explored. Therefore, this study aims to identify lncRNA signatures applicable to patients with gliomas across all grades and explore their clinical significance and potential biological mechanisms. Data used in this study were obtained from TCGA, CGGA, and GEO datasets to identify key lncRNA signatures in gliomas through differential and survival analyses and machine learning algorithms. We examined their associations with the clinical characteristics, gene mutations, diagnosis, and prognosis of gliomas. Functional enrichment analysis was employed to elucidate the potential biological mechanisms associated with these significant lncRNA signatures. We explored competing endogenous RNA (ceRNA) regulatory networks. We found that NDUFA6-DT emerged as a significant lncRNA signature in gliomas, with reduced NDUFA6-DT expression associated with a worse prognosis in gliomas. Nomogram analysis incorporating NDUFA6-DT expression levels exhibited excellent prognostic and predictive capabilities. Functional annotation suggested that NDUFA6-DT might influence immunological responses and synaptic transmission, potentially modifying glioma initiation and progression. The associated ceRNA network revealed the possible presence of the NDUFA6-DT-miR-455-3p-YWHAH/YWHAG axis in low-grade glioma (LGG) and glioblastoma multiforme (GBM), regulating the PI3K-AKT signaling pathway and influencing glioma cell survival and apoptosis. We believe that NDUFA6-DT is a novel lncRNA linked to glioma diagnosis and prognosis, potentially becoming a pivotal biomarker for glioma.
Open AccessLncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas
Gliomas are the most prevalent primary malignant tumors affecting the brain, with high recurrence and mortality rates. Accurate diagnoses and effective treatment challenges persist, emphasizing the need for identifying new biomarkers to guide clinical decisions. Long noncoding RNAs (lncRNAs) hold potential as diagnostic and therapeutic biomarkers in cancer. However, only a limited subset of lncRNAs in gliomas have been explored. Therefore, this study aims to identify lncRNA signatures applicable to patients with gliomas across all grades and explore their clinical significance and potential biological mechanisms. Data used in this study were obtained from TCGA, CGGA, and GEO datasets to identify key lncRNA signatures in gliomas through differential and survival analyses and machine learning algorithms. We examined their associations with the clinical characteristics, gene mutations, diagnosis, and prognosis of gliomas. Functional enrichment analysis was employed to elucidate the potential biological mechanisms associated with these significant lncRNA signatures. We explored competing endogenous RNA (ceRNA) regulatory networks. We found that NDUFA6-DT emerged as a significant lncRNA signature in gliomas, with reduced NDUFA6-DT expression associated with a worse prognosis in gliomas. Nomogram analysis incorporating NDUFA6-DT expression levels exhibited excellent prognostic and predictive capabilities. Functional annotation suggested that NDUFA6-DT might influence immunological responses and synaptic transmission, potentially modifying glioma initiation and progression. The associated ceRNA network revealed the possible presence of the NDUFA6-DT-miR-455-3p-YWHAH/YWHAG axis in low-grade glioma (LGG) and glioblastoma multiforme (GBM), regulating the PI3K-AKT signaling pathway and influencing glioma cell survival and apoptosis. We believe that NDUFA6-DT is a novel lncRNA linked to glioma diagnosis and prognosis, potentially becoming a pivotal biomarker for glioma.
- Open Access
- 26 December 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-19
Key Cell Types and Biomarkers in Heart Failure Identified through Analysis of Single-Cell and Bulk RNA Sequencing Data
Heart failure (HF) is a complex clinical syndrome resulting from various cardiac diseases and a significant medical issue worldwide. Although the role of inflammation in HF pathogenesis is well-known, the specific cell types and regulatory molecules involved remain poorly understood. Here, we identified key cell types and novel biomarkers via an analysis of single-cell and bulk RNA sequencing data obtained from patients with two major HF types of ischemic cardiomyopathy and dilated cardiomyopathy. Myeloid cells were identified as the primary cell population involved in HF through cellular fraction and gene set enrichment analysis. Additionally, differential analysis of myeloid cells revealed crosstalk between cellular communication and cytokine-regulated immune responses in HF, with the MIF pathway emerging as a crucial immune regulatory pathway. The CD74/CXCR4 receptor complex in myeloid cell subgroup Mφ2 was significantly upregulated, potentially acting as a crucial regulator in HF. Upon receiving the MIF signal molecule, the CD74/CXCR4 receptor can activate NF-κB signaling to produce chemokines and thereby enhance the inflammatory response. CD74 and CXCR4 may serve as biomarkers and treatment targets for HF.
- 26 December 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-19
Open AccessKey Cell Types and Biomarkers in Heart Failure Identified through Analysis of Single-Cell and Bulk RNA Sequencing Data
Heart failure (HF) is a complex clinical syndrome resulting from various cardiac diseases and a significant medical issue worldwide. Although the role of inflammation in HF pathogenesis is well-known, the specific cell types and regulatory molecules involved remain poorly understood. Here, we identified key cell types and novel biomarkers via an analysis of single-cell and bulk RNA sequencing data obtained from patients with two major HF types of ischemic cardiomyopathy and dilated cardiomyopathy. Myeloid cells were identified as the primary cell population involved in HF through cellular fraction and gene set enrichment analysis. Additionally, differential analysis of myeloid cells revealed crosstalk between cellular communication and cytokine-regulated immune responses in HF, with the MIF pathway emerging as a crucial immune regulatory pathway. The CD74/CXCR4 receptor complex in myeloid cell subgroup Mφ2 was significantly upregulated, potentially acting as a crucial regulator in HF. Upon receiving the MIF signal molecule, the CD74/CXCR4 receptor can activate NF-κB signaling to produce chemokines and thereby enhance the inflammatory response. CD74 and CXCR4 may serve as biomarkers and treatment targets for HF.
- Open Access
- 24 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (4) , 587
Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin α4β7/MAdCAM-1 in Flow
MAdCAM-1 binds to integrin α4β7, which mediates the rolling and arrest of circulating lymphocytes upon the vascular endothelia during lymphocytic homing. The calcium response by adhered lymphocytes is a critical event for lymphocyte activation and subsequent arrest and migration under flow. However, whether the interaction of integrin α4β7 /MAdCAM-1 can effectively trigger the calcium response of lymphocytes remains unclear, as well as whether the fluid force affects the calcium response. In this study, we explore the mechanical regulation of integrin α4β7-induced calcium signaling under flow. Flou-4 AM was used to examine the calcium response under real-time fluorescence microscopy when cells were firmly adhered to a parallel plate flow chamber. The interaction between integrin α4β7 and MAdCAM-1 was found to effectively trigger calcium signaling in firmly adhered RPMI 8226 cells. Meanwhile, increasing fluid shear stress accelerated the cytosolic calcium response and enhanced signaling intensity. Additionally, the calcium signaling of RPMI 8226 activated by integrin α4β7 originated from extracellular calcium influx instead of cytoplasmic calcium release, and the signaling transduction of integrin α4β7 was involved in Kindlin-3. These findings shed new light on the mechano-chemical mechanism of calcium signaling in RPMI 8226 cells induced by integrin α4β7.
- 24 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (4) , 587
Open AccessForce-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin α4β7/MAdCAM-1 in Flow
MAdCAM-1 binds to integrin α4β7, which mediates the rolling and arrest of circulating lymphocytes upon the vascular endothelia during lymphocytic homing. The calcium response by adhered lymphocytes is a critical event for lymphocyte activation and subsequent arrest and migration under flow. However, whether the interaction of integrin α4β7 /MAdCAM-1 can effectively trigger the calcium response of lymphocytes remains unclear, as well as whether the fluid force affects the calcium response. In this study, we explore the mechanical regulation of integrin α4β7-induced calcium signaling under flow. Flou-4 AM was used to examine the calcium response under real-time fluorescence microscopy when cells were firmly adhered to a parallel plate flow chamber. The interaction between integrin α4β7 and MAdCAM-1 was found to effectively trigger calcium signaling in firmly adhered RPMI 8226 cells. Meanwhile, increasing fluid shear stress accelerated the cytosolic calcium response and enhanced signaling intensity. Additionally, the calcium signaling of RPMI 8226 activated by integrin α4β7 originated from extracellular calcium influx instead of cytoplasmic calcium release, and the signaling transduction of integrin α4β7 was involved in Kindlin-3. These findings shed new light on the mechano-chemical mechanism of calcium signaling in RPMI 8226 cells induced by integrin α4β7.